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A B S T R A C T
Human T-cell lymphotropic virus type 1 (HTLV-1) can cause
adult T-cell leukaemia/lymphoma (ATLL). Two patients
originating from the Caribbean area with ATLL are described.
The first patient developed respiratory insufficiency due to
acute T-cell leukaemia. The diagnosis was suspected because
of characteristics of abnormal lymphocytes in the blood
smear. The second patient had lymphadenopathy and
developed severe hypercalcaemia. Both patients were typical
cases of ATLL. The pathogenesis, clinical manifestations,
pitfalls and treatment of this intriguing disease are discussed.
I N T R O D U C T I O N
Infection with human T-cell lymphotropic virus type 1
(HTLV-1) may cause a distinctive malignancy, adult T-cell
leukaemia/lymphoma (ATLL). The clinical features of ATLL
can be divided into four different subtypes; acute, chronic,
smouldering, and a lymphoma type. This HTLV-1-associated
malignancy occurs mainly in Japan, the Caribbean area,
Africa and parts of South America. This disease is rare in
Europe. We describe two patients originating from the
Caribbean with ATLL, one suffering from an acute T-cell
leukaemia and the other from the lymphoma type. We also
discuss the possible pitfalls of this disease, such as hyper-
calcaemia and infection with Strongyloides stercoralis.
C A S E  R E P O R T
Patient 1
A 36-year-old female was admitted to the pulmonary depart-
ment of our hospital because of rapidly progressive short-
ness of breath. She was born in French-Guyana and had
never been ill before. On physical examination she was
tachypnoeic with a breathing rate of 30/min. Physical exam-
ination of the chest revealed no abnormalities. The tem-
perature was 38 °C, no lymph nodes were palpable, and liver
and spleen were not enlarged. Laboratory examination
showed lymphocytosis (leucocytes 34 x 109/L, with 32%
atypical lymphocytes), elevated LDH 2684 U/L (normal value
450 U/L), and hypoxaemia; pH 7.42, pO2 41.9 mmHg, pCO2
32 mmHg, O2 saturation 79%. Chest X-ray showed fine
reticular infiltrates of both lungs. She was treated for atyp-
ical pneumonia with intravenous erythromycin, oxygen and
inhalation treatment with salbutamol and ipratropium. HIV
serology proved to be negative. Two days later she was trans-
ferred to the intensive care unit for mechanical ventilation
because of respiratory insufficiency. A bronchoscope showed
no abnormalities, but lavage showed atypical lymphocytes.
The next day, the haematologist was asked to look at the
blood smear, which showed typical cleaved and cerebriform
lymphocytes (figures 1 and 2). The diagnosis of HTLV-1
infection with acute T-cell leukaemia was suspected and
immediately confirmed by immunological typing of these
lymphocytes; CD3/CD4 positive, CD8 negative, CD5 positive,
CD25 positive and CD7 negative. Antibodies to HTLV-1 were
positive. She was treated with CHOP chemotherapy
(cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2,
vincristine 1.4 mg/m2 and prednisolone 100 mg) and
improved dramatically. After four days she could be trans-
ferred to the haematology department for further treatment.
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C A S E  R E P O R T
Microbiological examination of the stool showed Strong-
yloides stercoralis for which she was successfully treated with
ivermectine. She received cotrimoxazole (480 mg/day) as
prophylaxis for Pneumocystis carinii pneumonia. The ATL
was treated with six cycles of CHOP chemotherapy result-
ing in a clinical remission. Eleven months later the ATL
relapsed, showing a rise in leucocyte count from 4.8 to
40.9 x 109/L with 88% lymphocytes, hypercalcaemia (cal-
cium 2.91 mmol/L) and serum LDH elevated to 1454 U/L.
No lymph nodes were palpable. The hypercalcaemia was
treated with intravenous pamidronate. The ATL was treated
with another two cycles of CHOP chemotherapy, followed
by DHAP (dexamethasone, high ARA-C, cisplatinum),
zidovudine/interferon-alpha, and fludarabine, respectively.
Despite these efforts she died of refractory disease four
months after the relapse. Her identical twin sister also
appeared to be HTLV-1 positive, without any symptoms.
Patient 2
A 64-year-old man from Surinam was admitted to our
outpatient clinic because of lymphadenopathy. Ten days
previously he had noticed enlarged axillary and inguinal
lymph nodes. He had no complaints of weight loss, night
sweats or fever. On physical examination he appeared well,
and had axillary and inguinal lymph nodes between 2 and
5 cm in diameter. Liver and spleen were not enlarged.
Laboratory examination showed no abnormalities, except
for an elevated LDH of 589 U/L (normal value <450 U/L).
Serum calcium was normal (2.42 mmol/L). Chest X-ray
and sonography of the abdomen were normal. HIV ser-
ology was negative. Cytological punctures of different lymph
nodes showed small lymphocytic cells between large atyp-
ical lymphoblasts with high mitotic activity. These cells were
positive for CD3, CD4, HLA-DR and negative for CD7, CD8
and CD25. Bone marrow examination showed normal red,
white, and megakarocyte distribution but with clusters of
lymphocytes with identical immunological markers. A T-cell
non-Hodgkin’s lymphoma was suspected and HTLV-1
serology was performed, which proved to be positive. Before
we could discuss these results with the patient, he was
admitted to hospital because of severe somnolence. This was
due to severe hypercalcaemia (serum calcium 4.52 mmol/L,
albumin 32 g/L and LDH 1484 U/L). He was treated with
intravenous pamidronate, resulting in an improvement in
his clinical condition. It was concluded that this patient had
an HTLV-1-associated T-cell NHL, stage 4A, and treatment
with CHOP chemotherapy was started. Cotrimoxazole
480 mg daily was given for Pneumocystis carinii prophy-
laxis. Strongyloides stercoralis was not found in the stools
of this patient. After six cycles of CHOP chemotherapy,
physical examination and CT scan analysis showed a
complete remission. Two months after the last cycle of
chemotherapy, the disease relapsed with enlarged lymph
nodes, elevated calcium level of 4.28 mmol/L and elevated
LDH 680 U/L. Again he was treated with pamidronate and
chemotherapy (dexamethasone, high-ARA and cisplatinum).
Because of the minor response after two cycles of DHAP,
zidovudine/interferon was given. Due to intolerance of
this combination and because of severe pancytopenia, the
latter treatment was stopped and fludarabine 25 mg/m2
for five consecutive days was given. During this treatment
he developed skin lesions with nodules and papules in
the neck region and he became somnolent, which turned
out to be due to involvement of the central nervous sys-
tems, which was apparent from the presence of malig-
nant lymphocytes in the cerebrospinal fluid. Following
the wish of the patient and his family, all treatment was
stopped and he died soon afterwards.
D I S C U S S I O N  
Epidemiology and pathogenesis 
Adult T-cell leukaemia/lymphoma (ATLL) was first reported
in Japan in 1977.1 ATLL is associated with the human 
T-lymphotropic virus type 1 (HTLV-1). HTLV-1 is an RNA-
containing retrovirus, which is endemic in Japan, parts of
South America, the Caribbean and areas of Central and
West Africa. Our two patients originated from French-
Guyana and Surinam, respectively.
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Figure 1
Cerebriform lymphocyte in the pheripheral blood of patient 1
Figure 2
Cleaved lymphocyte in the peripheral blood of patient 1
In endemic areas of Japan, antibodies to HTLV-1 are found
in up to 37% of healthy adults.2 However, only about 3%
of carriers develop ATLL. ATLL only occurs in adults. The
age of onset ranges from 24 to 85 years, with an average of
58 years. The aetiological association of HTLV-1 and ATLL is
based on a series of findings. First, areas of high incidence
of ATLL correspond with those of high prevalence of
HTLV-1 infection. Second, all patients with ATLL have
antibodies against HTLV-1. Third, HTLV-1 proviral DNA can
be found in ATLL neoplastic cells. Finally, HTLV-1
immortalises human CD4 T cells.3,4
The incubation period of ATLL is long, ranging from 10 to
30 years, although ATLL acquired from blood transfusion
may occur after a shorter period.5
HTLV-1 is not easily transmissible, since cell-cell contact is
generally required. Two major transmission routes have
been described. One is vertical transmission from mother
to child via HTLV-1 positive lymphocytes in breast milk.
The second important route is horizontal transmission
through sexual contact, frequently from husband to wife,
rarely from wife to husband. Virus-positive lymphocytes
have been detected in semen of seropositive men. Two other
transmission routes of HTLV-1 are blood products contain-
ing infected T cells and intravenous drug abuse. In the
Netherlands, every year 3 to 15 healthy blood donors are
found to have antibodies against HTLV-1.6
Most of the effects of HTLV-1 infection have been attributed
to the HTLV-1-encoded protein Tax (trans-activator of X).
This protein is a key regulator for immortalisation, trans-
formation, and oncogenesis of the HTLV-1-infected lympho-
cytes through its interaction with many cellular proteins.
Most of these proteins, including Tax, are not expressed at
detectable levels in cells in ATLL. Their role in the leu-
kemogenic process must therefore be limited to the early
stages.7,8
Human T-lymphotropic virus type 2 (HTLV-II) was isolated
in 1982 by Kalyanaraman from a patient with an unusual
T-cell variant of hairy cell leukaemia. It has subsequently
been isolated only rarely in lymphoid neoplasia, but is
prevalent in intravenous drug abusers.9
C L I N I C A L  M A N I F E S T A T I O N S
Four clinical subtypes of ATLL have been proposed.10
First, the acute leukaemia type, representing 57% of the
patients, in which a leukaemic manifestation of the disease
is seen (patient 1). Hypercalcaemia and elevated LDH levels
are common. Second, a lymphoma type (about 19% of the
patients) without lymphocytosis and with histologically
proven lymphadenopathy with or without extranodal lesions
(patient 2). Third, a chronic type (about 19% of the patients)
with more than 3.5 x 109/L T lymphocytosis, LDH value up
to two times the normal upper limit, and no hypercalcaemia.
Lymphadenopathy and involvement of liver, spleen and lung
may be present. Finally, the smouldering type, representing
the remaining patients, with a normal lymphocyte count,
but with at least 5% abnormal T lymphocytes in peripheral
blood, no hypercalcaemia, LDH value of up to 1.5 times the
normal upper limit, and no lymphadenopathy or liver and
spleen involvement.
The most common physical findings at presentation are
lymphadenopathy, skin lesions, hepatomegaly and
splenomegaly. Rapid development of diffuse peripheral
lymphadenopathy without mediastinal involvement, as in
our second patient, is typical. The skin lesions in ATLL are
variable, including nodules and papules as in patient 2,
localised erythema and plaques, and generalised erythro-
derma. A biopsy of skin lesions usually reveals dermal or
epidermal infiltration of malignant T cells. The skin lesions
in ATLL often resemble mycosis fungoides, a low-grade
cutaneous T-cell lymphoma. Characteristically, mycosis
fungoides progresses from an eczematous stage to plaques
and finally to tumours. Circulating lymphocytes with
cleaved or cerebriform nuclei are highly suggestive of ATLL
(figures 1 and 2). This emphasises the importance of exam-
ination of the blood smear. The surface phenotype of
ATLL cells characterised by monoclonal antibodies is
CD3-positive, CD4-positive, CD7-negative, CD8-negative,
and CD25-positive.2 These findings suggest that ATLL
cells originate from the CD4 subset of mature T cells.
Elevated serum calcium levels are seen in most patients
with aggressive disease. Our two patients also developed
this complication. Parathyroid-hormone-related protein
(PTHrP), probably induced by Tax protein, is released from
ATLL cells in patients with hypercalcaemia and stimulates
osteoclasts.11 There is a much lower rate of replication of
HTLV-1 than of HIV. HTLV-1 can impair the immune
response, but less dramatically than HIV. Opportunistic
infections are frequent in patients with ATLL. The spectrum
of agents that cause these infections is similar to that seen
in AIDS, including protozoa, fungi and viruses.
Strongyloidiasis (as in patient 1) is frequent and may be
associated with hyperinfection and gram-negative bacter-
aemia, which is often fatal.12 Other diseases associated with
HTLV-1 infection are HTLV-1 uveitis and tropical spastic
paraparesis with hyperreflexia, urinary bladder disturbances
and muscle weakness.2
P R O G N O S I S  A N D  T R E A T M E N T
Survival of patients with acute and lymphoma types of
ATLL is poor, being 6.2 months for acute type, 10.2
months for lymphoma type and 24.3 months for chronic
type ATLL. Several features were found to be predictive of
shortened survival: poor performance status, age >40 years,
hypercalcaemia, high lactate dehydrogenase, and increased
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tumour bulk.10 There is no consensus on the best available
therapy for ATLL. For acute and lymphoma type ATLL,
combination chemotherapy can be effective. Complete
response rates of 30 to 40% are reported with different
combinations of drugs (CHOP, MACOP-B, PROMACE),
but no one regimen appears superior.10,12 Although these
combinations of chemotherapy have improved response
rates, this has not translated into increased survival due
to early relapse. Autologous and allogeneic bone marrow
transplantation have been reported with little success.13,14
The combination of zidovudine and interferon-alpha has
activity against ATLL, even in patients in whom prior
cytotoxic therapy has failed. With oral zidovudine (200 mg
five times daily) and interferon-alpha (five to ten million
units daily) subcutaneously, responses were achieved in
50 to 60% of the patients.15,16 Profound pancytopenia is
the major toxicity of this combination treatment in these
high doses. We encountered such side effects in patient 2. 
Central nervous system involvement may develop in as many
as 10% of patients with ATLL.17 Meningeal relapse after ini-
tial treatment may occur in patients not receiving prophy-
lactic intrathecal therapy. Therefore, it is recommended that
the cerebrospinal fluid is analysed at diagnosis and CNS
prophylaxis is given to all patients with acute and lymphoma-
type ATLL. Our two patients did not receive CNS prophy-
laxis, and in patient 2 meningeal involvement occurred at
the end of the disease.
Prevention of infection is extremely important during
treatment of ATLL. Prophylactic use of cotrimoxazole is now
routine, but antifungal and antiviral agents should be con-
sidered in all patients with acute or lymphoma-type ATLL.
Stools from all patients should be screened at diagnosis and
any patients positive for Strongyloides should be treated
appropriately.10 In the first patient Strongyloides was found
and was successfully treated with ivermectine. 
Treatment of patients with ATLL remains disappointing.
The best treatment is prevention of infection with HTLV-1.
The most important way to achieve this is to discourage
breastfeeding by women positive for HTLV-1 antibodies. We
assume that the first patient and her identical twin sister
were infected by breast milk. Because only a minority (<5%)
of the HTLV-1 carriers develop ATLL, prophylactic antiretro-
viral treatment is not recommended at this moment. In most
Western countries all donated blood is tested for HTLV-1
antibodies. No transfusion recipients have seroconverted
since screening started, even among patients who have
received many transfusions.
In summary, the blood smear remains a simple and effective
examination, but is often undervalued. Severe hypercal-
caemia can be one of the major symptoms of ATLL, espe-
cially in the acute and the lymphoma type. Stools of all
patients with ATLL should be examined for Strongyloides.
Finally, analysis of the cerebrospinal fluid in all patients with
acute and lymphoma type ATLL is recommended at diagno-
sis, and these patients should be given CNS prophylaxis. 
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